← Search organizationsOpenPolis
FDANonrulemakingFDA-2017-D-6209

Who commented on this docket

Assessing User Fees Under the Biosimilar User Fee Amendments of 2017

1 organizations filed 1 public comment on Assessing User Fees Under the Biosimilar User Fee Amendments of 2017, at the Food and Drug Administration. The comment window closed 2924d ago.

Organizations
1
Comments
1
RIN
—
Comment window
closed 2924d ago

Commenters (1)

View this docket on regulations.gov →

Attribution is name-based and imperfect. regulations.gov data is public record.

Who Commented on Assessing User Fees Under the Biosimilar User Fee Amendments of 2017 (FDA-2017-D-6209) | OpenPolis